 Healio | Combination of ibrutinib and rituximab shows promise against chronic ... News-Medical.net A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Cancer Treatment Could Help Against “Aggressive” Leukemia Combination of ibrutinib and rituximab produced high response rates in high ... Ibrutinib Effective and Safe Treatment Option in CLL |
